Beam Therapeutics Stock
Developer of genome editing technologies.
Sign up today and learn more about Beam Therapeutics Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Beam Therapeutics Stock
Over half of the genetic errors associated with disease result from a single-letter change in the billions of bases that form the genome. In other cases, certain natural genetic variations in DNA are known to protect against disease. By changing a single letter – to eliminate errors or write in protective changes – in enough cells, base editing may help us prevent, modify, and even cure a wide range of diseases affecting patients’ lives.
Investors
ARCH Venture Partners
Grail, Prime Medicine, Aledade, Codiak Biosciences, Mindstrong, Metacrine, Beam Therapeutics
Funding History
April 2018 | $13.0M |
---|---|
May 2018 | $74.0M |
Management
Co-Founder
J. Keith Joung
Chief Scientific Officer
Giuseppe Ciaramella
Co-Founder
David R. Liu
Co-Founder and Board Member
Feng Zhang
Chief Executive Officer and Board Member
John Evans
Press
Wall Streets Journal - Mar, 6 2019
Precision-Drug Startup Beam Therapeutics Raises $135 MillionGlobal University Venturing - May, 15 2018
Beam Therapeutics lasers in on $87m series A